

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : General University Hospital, Prague
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect of N115 on Coughing in IPF Patients
Details : Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 14, 2023
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : General University Hospital, Prague
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : N115 clinically and significantly reduced coughing/sneezing, fatigue, and increased SaO2 levels and synthesis of nasal nitric oxide. N115 Non-Steroidal Nasal Spray could be used as safe, effective treatment to help alleviate the symptoms associated with ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 05, 2021
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.
Details : Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Post-Acute COVID-19 Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 04, 2021
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague
Deal Size : Inapplicable
Deal Type : Inapplicable
Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection
Details : Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 01, 2021
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EmphyCorp N115 Reducing the Rate and Spread of COVID-19 with Nasal Nitric Oxide
Details : EmphyCorp's globally patented formula has Completed All Three Phases of Clinical Trials required by the FDA to prove safety and efficacy in treating the Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 07, 2020
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
